WO2001092464A3 - Therapeutic vaccine preparation and treatment for hiv viral infection - Google Patents
Therapeutic vaccine preparation and treatment for hiv viral infection Download PDFInfo
- Publication number
- WO2001092464A3 WO2001092464A3 PCT/NL2001/000431 NL0100431W WO0192464A3 WO 2001092464 A3 WO2001092464 A3 WO 2001092464A3 NL 0100431 W NL0100431 W NL 0100431W WO 0192464 A3 WO0192464 A3 WO 0192464A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- hiv
- treatment
- treating
- viral infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001274661A AU2001274661A1 (en) | 2000-05-31 | 2001-05-31 | Therapeutic vaccine preparation and treatment for hiv viral infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1015352A NL1015352C2 (en) | 2000-05-31 | 2000-05-31 | Antigen conjugation vaccination technique with host virus. |
NL1015352 | 2000-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001092464A2 WO2001092464A2 (en) | 2001-12-06 |
WO2001092464A3 true WO2001092464A3 (en) | 2002-04-11 |
Family
ID=19771480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2001/000431 WO2001092464A2 (en) | 2000-05-31 | 2001-05-31 | Therapeutic vaccine preparation and treatment for hiv viral infection |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001274661A1 (en) |
NL (1) | NL1015352C2 (en) |
WO (1) | WO2001092464A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU1824196C (en) * | 1991-02-25 | 1993-06-30 | Всесоюзный научно-исследовательский ветеринарный институт | Method for production of inactivated antigen of rabies virus to provide serologic reactions |
WO1993014197A1 (en) * | 1992-01-16 | 1993-07-22 | New York University | Hypericin treatment of vaccine agents for improved immunogenicity |
EP0562877A2 (en) * | 1992-03-27 | 1993-09-29 | ORTHO DIAGNOSTIC SYSTEMS INC. (a New Jersey corp.) | Cell fixative and method of staining cells without destroying the cell surface |
-
2000
- 2000-05-31 NL NL1015352A patent/NL1015352C2/en not_active IP Right Cessation
-
2001
- 2001-05-31 AU AU2001274661A patent/AU2001274661A1/en not_active Abandoned
- 2001-05-31 WO PCT/NL2001/000431 patent/WO2001092464A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU1824196C (en) * | 1991-02-25 | 1993-06-30 | Всесоюзный научно-исследовательский ветеринарный институт | Method for production of inactivated antigen of rabies virus to provide serologic reactions |
WO1993014197A1 (en) * | 1992-01-16 | 1993-07-22 | New York University | Hypericin treatment of vaccine agents for improved immunogenicity |
EP0562877A2 (en) * | 1992-03-27 | 1993-09-29 | ORTHO DIAGNOSTIC SYSTEMS INC. (a New Jersey corp.) | Cell fixative and method of staining cells without destroying the cell surface |
Non-Patent Citations (5)
Title |
---|
DATABASE WPI Week 9444, Derwent World Patents Index; AN 1994-356531, XP002167695 * |
G. KAMEN: "Acrolein and Mengo-Semliki virus immunity.", NATURE, vol. 192, 9 December 1961 (1961-12-09), London, GB, pages 986 - 987, XP000993519 * |
G. KAMEN: "Detection of acrolein by quantitative immunochemical analysis.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 72, 1949, San Diego, CA, USA, pages 18 - 21, XP000993499 * |
U. BACHRACH ET AL.: "Antivirus action of acrolein, glutaraldehyde and oxidized spermine.", JOURNAL OF GENERAL VIROLOGY, vol. 13, no. 3, December 1971 (1971-12-01), London, GB, pages 415 - 422, XP000993502 * |
U. BACHRACH ET AL.: "Effect of oxidized spermine and other aldehydes on the infectivity of vaccinia virus.", APPLIED MICROBIOLOGY, vol. 23, no. 2, February 1972 (1972-02-01), Washington, DC, USA, pages 232 - 235, XP000993498 * |
Also Published As
Publication number | Publication date |
---|---|
NL1015352C2 (en) | 2001-12-03 |
WO2001092464A2 (en) | 2001-12-06 |
AU2001274661A1 (en) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001068117A3 (en) | Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections | |
CA2632516C (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
SG156652A1 (en) | Yeast-based therapeutic for chronic hepatitis c infection | |
CY1105408T1 (en) | USE OF PARAPOX OVIS VIRUS STRAINS FOR THE PREPARATION OF ANCIENT MEDICINES AND ANTI-CANCER DRUGS | |
WO2002022686A3 (en) | Defensin-antigen fusion proteins | |
WO2001000232A3 (en) | Use of cpg as an adjuvant for hiv vaccine | |
WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
BG98522A (en) | Peptides including cytotoxic t-lymphocytic response to the virus of hepatite b | |
DE60331412D1 (en) | HIV vaccine and method of administration | |
BR0316291A (en) | Hcv vaccine, methods of preventing or treating an hcv infection in a mammal and vaccinating an individual, and using a hcv vaccine | |
Domm et al. | Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier | |
WO2003061602A3 (en) | Combination therapy for treatment of hiv infection | |
WO2002022687A3 (en) | Viral chemokine-tumur antigen fusion proteins | |
Moingeon et al. | Therapeutic vaccines against infectious diseases | |
WO2001092464A3 (en) | Therapeutic vaccine preparation and treatment for hiv viral infection | |
CA2350127A1 (en) | Avipox vector coding an hiv antigen and a cytokine | |
WO2020255009A3 (en) | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody | |
WO2003025002A3 (en) | Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection | |
ES2133408T3 (en) | NEW ISOLATES OF HIV-1 VIRUSES OF A SUBTYPE, AND THEIR DIFFERENTIAL DIAGNOSIS, VACCINE AGAINST HIV-1 INFECTION OF THIS SUBTYPE AND PROCEDURE TO PREPARE AND USE THE HIV-1 ISOLATE. | |
WO2004041200A3 (en) | Dna based plasmid formulations and vaccines and prophylactics containing the same | |
RU2682677C2 (en) | Method of post-exposure prevention of tick-borne encephalitis | |
WO2003073984A3 (en) | Tat as an immunogen | |
WO2001054652A8 (en) | A method of inducing autovaccination against hiv infection using structured treatment interruptions | |
WO2005027835A3 (en) | Therapeutic immunization of hiv-infected individuals | |
RU2001125429A (en) | TREATMENT OF CHRONIC VIRAL INFECTIONS M. VACCAE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CN IN JP KP KR RU US VN ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CN IN JP KP KR RU US VN ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |